All Updates

All Updates

icon
Filter
M&A
Partnerships
Eli Lilly partners with Radionetics Oncology to develop cancer radiotherapeutics
Precision Medicine
Jul 2, 2024
This week:
Partnerships
MGI Tech and Predica Diagnostics collaborate to develop Predica's targeted RNA sequencing tests
Precision Medicine
Yesterday
Partnerships
Renalytix partners with Steno Diabetes Center to advance precision medicine solutions for diabetes and chronic kidney disease
Precision Medicine
Yesterday
Partnerships
Myriad Genetics and Personalis cross-license patents for tumor-informed cancer treatment tests
Precision Medicine
Yesterday
Funding
Element Biosciences raises USD 277 million in Series D funding to commercialize AVITI DNA sequencer and support AVITI24 launch
Precision Medicine
Yesterday
Funding
Jacobi Robotics raises USD 5 million in seed funding to expand capacity
Smart Factory
Yesterday
M&A
Formlabs acquires Micronics for undisclosed sum to develop next-generation SLS printers
Additive Manufacturing
Yesterday
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Yesterday
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Yesterday
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Yesterday
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Yesterday
Precision Medicine

Precision Medicine

Jul 2, 2024

Eli Lilly partners with Radionetics Oncology to develop cancer radiotherapeutics

M&A
Partnerships

  • Eli Lilly has entered a strategic partnership with Radionetics Oncology, establishing a path to potentially acquire the company and gaining access to its pipeline of cancer radiotherapeutics.

  • The deal involves an upfront payment of USD 140 million from Lilly and the exclusive right to acquire Radionetics for USD 1 billion. The collaboration provides Lilly access to Radionetics' expertise in targeting novel GPCR proteins for cancer treatment. It also enables the advancement of Radionetics' lead drug candidate, 68Ga-R8760, which targets the MC2R protein related to a rare form of cancer. 

  • Radionetics Oncology is a clinical-stage radiopharmaceutical company developing novel radiotherapeutics targeting various oncology indications. The company is advancing a pipeline of novel small-molecule radioligands targeting GPCRs for the treatment of a broad range of cancers, including adrenocortical carcinoma, breast cancer, and lung cancer. 

  • Analyst QuickTake: This partnership is part of Eli Lilly’s ongoing effort to expand its radiopharmaceutical portfolio. In October 2023, the company acquired Point Biopharma to gain access to its radiogland pipeline. Additionally, in May 2024, the company inked a deal with Aktis Oncology , gaining worldwide rights to certain radiopharma therapeutics discovered by Aktis using the biotech’s miniprotein technology platform.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.